Compass Therapeutics Price Target Announced at $32.00/Share by D. Boral Capital

Dow Jones20:15 · Ratings

Compass Point Initiates Coverage On NCR Atleos With Buy Rating, Announces Price Target of $57

Benzinga19:55 · Ratings

Compass Point Downgrades Innovative Ind Props to Neutral, Lowers Price Target to $78

BenzingaDec 20 23:45 · Ratings

Compass Health Celebrates Second Donation From Longtime Partner for Its State-of-the-Art Regional Center for Intensive Behavioral Health Needs

GlobeNewswireDec 20 23:00

Compass Mining Scales Texas Operations With 25 MW Bitcoin Mining Facility, Plans Further Expansion

PR NewswireDec 20 22:00

Institutional Investors in Compass Diversified (NYSE:CODI) Lost 4.3% Last Week but Have Reaped the Benefits of Longer-term Growth

Simply Wall StDec 19 22:28